Get started
Author

Laura Magnano Mayer

Suppression of Th1 and Th17, but not Th2, responses in a CD8+ T cell-mediated model of oral tolerance
2009 · PM Arnaboldi, F Roth-Walter, et al. · Mucosal Immunology · 27
PDF
Interactions between peripheral blood CD8 T lymphocytes and intestinal epithelial cells (iEC)
1998 · F A Arosa, C Irwin, et al. · Clinical & Experimental Immunology · 21
Synergy between B cell differentiation factors and interleukin 2, using a monoclonal system.
1985 · L Mayer, M K Crow, et al. · The Journal of Immunology · 18
Basic and clinical overview of the mucosal immune system.
1996 · L S Toy, L Mayer · PubMed · 17
Attenuation of TNF-driven murine ileitis by intestinal expression of the viral immunomodulator CrmD
2010 · A Viejo-Borbolla, A P Martin, et al. · Mucosal Immunology · 13
PDF
Three dose induction regimen of infliximab (Remicade) is superior to a single dose in patients with Crohns disease (CD)
2001 · L MAYER · The American Journal of Gastroenterology · 12
“Immune/Non-Immune Cell Interactions in Intestinal Inflammation” Workshop
1997 · C. Fiocchi, S. M. Collins, et al. · Inflammatory Bowel Diseases · 7
PDF
Comparative pharmacokinetics of single and multiple-dose infliximab in Crohns disease patients
2002 · A. Boyle, R. Tawadros, et al. · 5
Pathogenesis of inflammatory bowel disease: evolving concepts.
1996 · L Mayer, X Y Yio, et al. · PubMed · 5
CT-1498: A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2025 · Krish Patel, Joanna Rhodes, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study
2025 · Benoit Tessoulin, James Harnett, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
49 | Combination Treatment With Novel Bcl2 Inhibitor Sonrotoclax (bgb‐11417) + Zanubrutinib Induces High Rate of Complete Remission in Relapsed/refractory Mantle Cell Lymphoma
2025 · C. S. Tam, M. Lasica, et al. · Hematological Oncology · 2
PDF
Abstract CT243: Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
2024 · Geoffrey Chong, Michal Taszner, et al. · Cancer Research · 2
Immunology of inflammatory bowel disease
1990 · L Mayer · Current Opinion in Gastroenterology · 2
ORAL ABSTRACT: CT-1498 A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bi-Specific Chimeric Antigen Receptor (Car) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2025 · Krish Patel, Joanna Rhodes, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-1498 A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bi-Specific Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2025 · Krish Patel, Joanna Rhodes, et al. · Clinical Lymphoma Myeloma & Leukemia
242 | Long‐term Efficacy and Survival Outcomes With Odronextamab in Relapsed/refractory Follicular Lymphoma (r/r Fl): 2‐year Follow‐up From the Phase 2 Elm‐2 Study
2025 · S. Luminari, M. Taszner, et al. · Hematological Oncology
PDF
CLL-186 Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia
2024 · Stephen Opat, Farrukh T. Awan, et al. · Clinical Lymphoma Myeloma & Leukemia
Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia
2024 · Stephen Opat, Farrukh T. Awan, et al. · Clinical Lymphoma Myeloma & Leukemia
Health-related quality of life (HRQoL), functioning, and symptoms with odronextamab monotherapy in patients (pts) with relapsed or refractory follicular lymphoma (R/R FL) by POD24 status in the ELM-2 study.
2024 · Jose Caetano Villasboas, Laura Magnano Mayer, et al. · Journal of Clinical Oncology
The Wiskott-Aldrich Syndrome protein alters Treg homeostasis via reduced strength of T cell receptor signaling.
2011 · E Boden, V Ahuja, et al. · Inflammatory Bowel Diseases
P108 Visilizumab Therapy in Subjects With Moderate-to-severe, Refractory Crohn's Disease
2007 · D.W. Hommes, S.R. Targan, et al. · Journal of Crohn s and Colitis Supplements
PDF
Therapeutic advances and issues of patient adherence in the treatment of ulcerative colitis
2007 · Edward V. Loftus, S P Kane, et al. · Gastroenterología y Hepatología
Immunology of diseases of the oral cavity. Chapter 89.
2005 · Stephen Challacombe, Pepe Shirlaw, et al. · Research Portal (King's College London)
Local immune responses in tuberculosis
2005 · Stephen Challacombe, Pepe Shirlaw, et al. · Academic Press eBooks
Works count: 30
Citation count: 137
H-index: 7
I10-index: 6
Year
Topic
Type